Pharma / Biotech

Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.



Related Articles

Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.

Drug Metab Pharmacokinet. 2019 Oct 25;:

Authors: Goto E, Horinaka S, Ishimitsu T, Kato T

Abstract
BACKGROUND: The anticoagulant actions of oral direct factor Xa (FXa) inhibitors can be inferred from their observed plasma concentrations; however, the steady-state pharmacokinetics (PK) of different FXa inhibitors have not been compared in clinically.
METHODS: The sensitivity of the rivaroxaban, apixaban, and edoxaban in the STA-Liquid Anti-FXa assay were compared, and the anti-FXa plasma concentrations were measured for PK assessments. Nonlinear mixed-effects modeling was used to assess population PK in 329 patients with nonvalvular atrial fibrillation or venous thromboembolism. Patients were followed up for an average of 3.6 years.
RESULTS: Sensitivity was similar among the three drugs in this assay, which could directly compare plasma concentrations instead of anti-FXa activities. Overall exposure was greatest in 5 mg BID apixaban relative to other drugs (p < 0.001). The geometric mean AUC for the 0 to 24-h interval was 4550 ng h/mL for apixaban, 2710 ng h/mL for 15 mg QD rivaroxaban, and 1290 ng h/mL for 60 mg QD edoxaban. The PKs of 2.5 mg BID apixaban or 15 mg QD rivaroxaban were associated with hemorrhagic events.
CONCLUSIONS: Apixaban was associated with greater exposure, higher trough concentrations in plasma compared with rivaroxaban or edoxaban. Furthermore, a higher plasma concentration may partially predict hemorrhagic events.

PMID: 32007354 [PubMed – as supplied by publisher]

Source link






Related posts

OXYCODONE HYDROCHLORIDE Solution [SpecGx LLC]

Newsemia

journal pharmacology; +664 new citations

Newsemia

ALL-DAY LIQUID FOUNDATION SPF 15 SUNSCREEN TRUE BEIGE (Octinoxate, Titanium Dioxide) Emulsion [H And M Hennes And Mauritz LP]

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy